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Blockade of the renin–angiotensin system (RAS) is a core thera-
peutic strategy in systolic heart failure.
1 The value of angiotensin-
converting enzyme (ACE) inhibitors was proven in two pivotal
trials conducted . 20 years ago. More recently, angiotensin
receptor blockers (ARBs) have also been shown to be beneﬁcial
in systolic heart failure both as an alternative to and when added
to an ACE inhibitor. Separately, mineralocorticoid receptor
antagonists (MRAs) reduce mortality and morbidity when added
to an ACE inhibitor or ARB (MRAs are not considered further
here). The latest approach to RAS blockade to be tested in clin-
ical practice is renin inhibition. Currently the efﬁcacy and safety of
the renin inhibitor aliskiren is being tested in two clinical trials in
heart failure, the Aliskiren Trial of Minimizing OutcomeS for
Patients with HEart failure (ATMOSPHERE) and the Aliskiren
Trial on Acute Heart Failure Outcomes (ASTRONAUT),
described previously in this journal.
2,3 However, on 20 December
2011, treatment in another study, the Aliskiren Trial In Type 2
Diabetes Using Cardio-Renal Disease Endpoints (ALTITUDE),
was stopped on the recommendation of its Data Monitoring
Committee (DMC).
2,3 ALTITUDE was comparing placebo or alis-
kiren 300 mg once daily, added to background ACE inhibitor or
ARB therapy in patients with diabetes and either (i) increased
urinary albumin excretion or (ii) both a reduced estimated glom-
erular ﬁltration rate (eGFR 30–60 mL/min/1.73 m
2) and estab-
lished cardiovascular disease. The primary outcome in
ALTITUDE is a composite of cardiovascular death, resuscitated
sudden death, non-fatal myocardial infarction, non-fatal stroke,
unplanned hospitalization for heart failure, end-stage renal
disease, renal death, or doubling of baseline serum creatinine
concentration, sustained for at least a month. As a result of the
DMC recommendation, ALTITUDE is currently being closed
out in an orderly fashion. The basis of the DMC recommendation
was futility (i.e. no prospect of demonstrating the treatment
beneﬁt anticipated in the protocol) as well as safety concerns.
These concerns included renal dysfunction, hyperkalaemia, and
hypotension (which are unsurprising) as well as an excess of
strokes. In the publically released information, the number of
patients experiencing a non-fatal stroke in the placebo group
was 85 (2.0%) and 112 (2.6%) in the aliskiren group (nominal,
unadjusted, P-value 0.04).
6 Although this unexpected ﬁnding has
provoked concern and discussion, the reported numbers do not
represent the ﬁnal number of events in ALTITUDE (at the time
of the DMC’s recommendation it was estimated that approxi-
mately a third of events remained to be collected and adjudi-
cated). Consequently, while the apparent imbalance in strokes
may persist or increase, it may also attenuate. Furthermore,
given all prior data relating use of antihypertensive therapy to a
reduced incidence of stroke in patients with diabetes, it is also
possible that the imbalance in strokes represents a chance
ﬁnding.
7–9
In response to these ﬁndings it has been recommended that
dual aliskiren and ACE inhibitor/ARB therapy not be used in
patients with both hypertension (the current indication for
aliskiren) and diabetes or moderate to severe renal dysfunction
(eGFR ,60 mL/min/1.73 m
2).
10 This recommendation has led
to questions about the use of dual aliskiren therapy in patients
with diabetes in the ongoing ATMOSPHERE trial (and, to a
lesser extent, also the ASTRONAUT trial which has almost
ﬁnished recruitment and will complete follow-up this year). In
ATMOSPHERE, patients with systolic heart failure and an
elevated B-type natriuretic peptide (BNP) or N-terminal pro
BNP ( NT-proBNP) concentration are randomized in equal
proportions to receive either enalapril 10 mg twice daily,
aliskiren 300 mg once daily, or the combination of both drugs.
3
ATMOSPHERE is an event-driven trial with a primary
composite outcome of cardiovascular death or heart failure
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TUDE should not lead to any alteration in the conduct of
ATMOSPHERE. The reasons for taking this view are discussed
in detail below.
Different patient populations
The patients in ALTITUDE are quite different from those in
ATMOSPHERE. Virtually all patients in ALTITUDE had treated
hypertension and the median systolic blood pressure (SBP) was
135 (Q1 126, Q3 150) mmHg. In ATMOSPHERE, 59% of patients
recruited to date have a history of hypertension and the median
SBP at baseline is 120 (Q1 110, Q3 135) mmHg. Whereas all
patients in ALTITUDE had diabetes, only 29% of the   5500
patients already randomized in ATMOSPHERE have this
co-morbidity (and only one-third of these are receiving dual aliski-
ren and enalapril therapy). Patients with an eGFR , 35 mL/min/
1.73 m
2 cannot be randomized in ATMOSPHERE. A much
smaller proportion of patients in ATMOSPHERE have a moder-
ately (,60 mL/min/1.73 m
2; currently 27%) or substantially
(,45 mL/min/1.73 m
2; currently 7%) reduced eGFR, compared
with ALTITUDE (68% and 33%, respectively). More importantly,
only 11% of patients in ALTITUDE had heart failure at baseline
and, of those with a measurement of left ventricular ejection frac-
tion (EF, n ¼ 258), only 62 patients had an EF ≤ 35%.
Different study design: the
importance of the active run-in
periods
Recognizing that patients with heart failure may suffer hypotension,
renal dysfunction, and hyperkalaemia with dual RAS blockade,
ATMOSPHERE was designed with enalapril, followed by enalapril
plus aliskiren ‘open-label’ active run-in periods. Patients experien-
cing clinically important changes in blood pressure, creatinine/
eGFR, and potassium at the end of each of these periods were
unable to progress to the next treatment period/randomization
(Table 1).
3 It is expected that this design should protect against
some of the adverse effects seen in ALTITUDE which did not
have this design feature.
Prior experience with dual
renin–angiotensin system
blockade in heart failure
As mentioned above, dual RAS blockade with agents other than
aliskiren has been shown to be of beneﬁt in two separate trials.
Importantly, this beneﬁt appears unique to heart failure, possibly
because this syndrome is characterized by intense RAS activation.
Similar beneﬁt is not seen after myocardial infarction or in
patients with chronic arterial disease. Moreover, the beneﬁt of
dual ACE inhibitor and ARB therapy in heart failure was apparent
in patients who had and did not have diabetes, without any
evidence of heterogeneity of treatment effect in relation to this
co-morbidity (CHARM-Added, unpublished; and Val-HeFT
11). In
addition, dual ACE inhibitor plus ARB treatment was similarly
beneﬁcial in patients with, and in those without, renal dysfunction
(eGFR , 60 mL/min/1.73m
2) in Val-HeFT.
12
Prior experience with aliskiren
in heart failure
BeforeembarkingonATMOSPHERE,thesafetyofaddingaliskirento
anACEinhibitororARBwastestedinapilottrial,ALOFT,inpatients
withahistoryofhypertensionandheartfailure.
13–15Over3months,
the addition of aliskiren 150 mg daily was not associated with a clin-
ically important excess of elevations in potassium or creatinine,
including in patients with diabetes. ‘Efﬁcacy’ was assessed by meas-
urementofreductioninBNPswhich wassimilarlyreducedwithalis-
kiren vs. placebo in patients with and without diabetes.
16
Type of clinical events in
ATMOSPHERE compared with
ALTITUDE
The pattern of clinical events in patients with chronic systolic heart
failure is quite different from that of the type of patients enrolled in
ALTITUDE. In heart failure, cardiovascular death and heart failure
hospitalization are much more common than stroke (or myocar-
dial infarction) and, consequently, ATMOSPHERE is testing the
...............................................................................................................................................................................
Table 1 Safety monitoring criteria that need to be met at screening (before open-label active run-in) and randomization
(after open-label active run-in)
Parameter Screening visit (V1) Randomization visit (V4)
Hyperkalaemia K
+ ,5.0 mmol/L K
+ ,5.2 mmol/L
Renal dysfunction eGFR ≥40 mL/min/1.73 m
2 eGFR ≥35 mL/min/1.73 m
2
No decrease of eGFR of .25% from visit 1
BP No symptomatic hypotension No symptomatic hypotension
SBP ≥95 mmHg SBP ≥90 mmHg
AEs No AEs that preclude continuation according
to the investigator judgement
No AEs that preclude continuation according
to the investigator judgement
From Krum et al.
3
AE, adverse event; BP, blood pressure; eGFR, estimated glomerular ﬁltration rate; SBP, systolic blood pressure.
J.J.V. McMurray et al. 342effect of aliskiren on a different burden of disease (hence the
different primary and secondary endpoints in ALTITUDE and
ATMOSPHERE).
17,18
Ensuring patient safety: the role of
the Data Monitoring Committee
Lastly and most importantly, the safety of patients in ATMOS-
PHERE is ensured by the group of independent physicians (and a
statistician) on the DMC whose primary role is to protect the
safety of patients enrolled in this trial.
3 The DMC members are
the only individuals during the course of the trial aware of treat-
ment allocation, and these members have vast experience in con-
ducting and monitoring trials in heart failure, especially trials with
RAS blockers. The DMC have been informed of the results of
ALTITUDE and have reviewed the ﬁndings of ATMOSPHERE in
the light of this new information. Their recommendation is that
ATMOSPHERE should continue as planned (DMC communication
to ATMOSPHERE co-chairs 20 December 2011).
Based on the above considerations, the authors (who are the
academic members of the Executive Committee of the trial)
strongly believe that the ATMOSPHERE study should continue
unchanged (including continued recruitment of patients with any
of a history of hypertension, diabetes, or reduced renal function)
with whatever scrutiny is deemed appropriate by the DMC. We
believe that this situation is analogous to a previous example of
a safety concern raised about a treatment in one condition but
the same treatment continuing to be tested in a trial in heart
failure.
19–21 Of course, all patients are being informed of the
results of ALTITUDE and will only continue in ATMOSPHERE if
they are willing to sign an updated consent form.
Conﬂict of interest: All authors are members of the Executive
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